Can Fite Biopharma Ltd - Asset Resilience Ratio

Latest as of December 2025: 31.66%

Can Fite Biopharma Ltd (CANF) has an Asset Resilience Ratio of 31.66% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Can Fite Biopharma Ltd (CANF) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

ILA3.01 Million

≈ $8.08K USD Cash + Short-term Investments

Total Assets

ILA9.51 Million

≈ $25.51K USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2006–2025)

This chart shows how Can Fite Biopharma Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see CANF total assets.

Liquid Assets Composition Over Time

This chart breaks down Can Fite Biopharma Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Can Fite Biopharma Ltd (CANF) long-term investment share to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	ILA0.00	0%
Short-term Investments	ILA3.01 Million	31.66%
Total Liquid Assets	ILA3.01 Million	31.66%

Asset Resilience Insights

Very High Liquidity: Can Fite Biopharma Ltd maintains exceptional liquid asset reserves at 31.66% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Can Fite Biopharma Ltd Industry Peers by Asset Resilience Ratio

Compare Can Fite Biopharma Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%

Annual Asset Resilience Ratio for Can Fite Biopharma Ltd (2006–2025)

The table below shows the annual Asset Resilience Ratio data for Can Fite Biopharma Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	31.66%	ILA3.01 Million ≈ $8.08K	ILA9.52 Million ≈ $25.51K	-1.92pp
2024-12-31	33.57%	ILA3.06 Million ≈ $8.21K	ILA9.12 Million ≈ $24.45K	-12.92pp
2023-12-31	46.49%	ILA4.64 Million ≈ $12.45K	ILA9.99 Million ≈ $26.78K	-7.38pp
2022-12-31	53.87%	ILA5.00 Million ≈ $13.41K	ILA9.28 Million ≈ $24.89K	-18.95pp
2021-12-31	72.82%	ILA14.75 Million ≈ $39.54K	ILA20.25 Million ≈ $54.30K	+72.04pp
2020-12-31	0.79%	ILA75.00K ≈ $201.07	ILA9.52 Million ≈ $25.53K	+0.00pp
2019-12-31	0.78%	ILA64.00K ≈ $171.58	ILA8.17 Million ≈ $21.91K	-2.65pp
2018-12-31	3.43%	ILA273.00K ≈ $731.90	ILA7.95 Million ≈ $21.32K	-63.80pp
2006-12-31	67.23%	ILA28.08 Million ≈ $75.27K	ILA41.76 Million ≈ $111.96K	--

pp = percentage points

About Can Fite Biopharma Ltd

TA:CANF Israel Biotechnology

Market Cap

$3.93 Million

ILA1.47 Billion ILA

Market Cap Rank

#29132 Global

#420 in Israel

Share Price

ILA342.20

Change (1 day)

-1.69%

52-Week Range

ILA1.00 - ILA1500.00

All Time High

ILA1500.00